Dr. Zheng Wang 王征
Chief Physician
Department of Hepatobiliary Oncology and Liver Transplantation, Zhongshan Hospital, Fudan University, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical and minimally invasive treatment of primary and metastatic liver tumors, and liver transplantation.
Professional roles
- Vice Chair, Youth Committee of the Oncology Branch, Shanghai Medical Association
- Member, Liver Cancer Professional Committee, China Anti-Cancer Association
- Member and Deputy Leader of the ALPPS Group, Digital Medicine Clinical Surgery Professional Committee, Chinese Research Hospital Association
- Youth Member, Organ Transplant Physician Branch and Minimally Invasive Surgery Physician Committee, Chinese Medical Doctor Association
Name order: in Chinese the family name comes first (Wang Zheng). Papers usually list the name as Zheng Wang or Wang Z.
Selected publications
126 papers on PubMed matched by name and affiliation; 18 as first or senior author since 2016. Most recent first- or senior-author papers:
- Hepatobiliary Surg Nutr, 2026 (first author): Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition). PubMed 42273581
- Lancet Gastroenterol Hepatol, 2026 (first author): Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial. PubMed 41319673
- Int J Radiat Oncol Biol Phys, 2025 (senior author): Prospective Phase 2 Clinical Trial of Carbon Ion Radiation Therapy Combined With Chemotherapy for Locally Advanced Pancreatic Carcinoma. PubMed 40614787
- Lancet, 2025 (first author): Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial. PubMed 41125112
- Hepatobiliary Surg Nutr, 2025 (first author): Auxiliary liver transplantation using otherwise-discarded liver allograft combined with associating liver partition and portal vein ligation for staged hepatectomy for unresectable colorectal liver metastases. PubMed 40893759
- J Immunother Cancer, 2025 (senior author): Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria. PubMed 39824532
- Int J Biol Macromol, 2024 (first author): Chitosan- and hyaluronic acid-based nanoarchitectures in phototherapy: Combination cancer chemotherapy, immunotherapy and gene therapy. PubMed 38795895
- Ann Transl Med, 2022 (senior author): Long-term outcomes and prognosis for patients with sarcomatoid hepatocellular carcinoma. PubMed 35530933
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion